Spero Cataland
Immunology and Microbiology · The Ohio State University
Publications
15
Citations
433
Est. group size
—
Recurring co-author estimate
Active years
13
Publishing since 2013
Spero Cataland's work focuses on rare blood and kidney disorders caused by problems in the complement system (a part of the immune system) and blood clotting pathways, including atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP), and immune thrombocytopenia. Much of the research involves clinical trials and long-term outcome studies evaluating drugs that block complement proteins (like ravulizumab and eculizumab) or target immune cells, aimed at improving treatment safety and effectiveness for patients with these conditions.
Publication output has been modest and uneven over the past decade, with a cluster of activity in 2020-2021 followed by a slower but continuing pace through 2023-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Expert consensus on the clinical management of congenital thrombotic thrombocytopenic purpura in Asia-Pacific: A modified Delphi panel
Blood · 2025
- Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials
Kidney Medicine · 2024
- Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)
Blood · 2024
- Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome
Journal of Comparative Effectiveness Research · 2023
- Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults
Kidney International Reports · 2021
- Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data
Clinical Nephrology · 2021
- Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of Two Phase 3 Studies
Blood · 2021
- Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296
Kidney International · 2021
- The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
Kidney International · 2020
- Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry
Kidney International Reports · 2020
- SO054ONE-YEAR EFFICACY AND SAFETY OF THE LONG ACTING C5 INHIBITOR RAVULIZUMAB FOR THE TREATMENT OF ATYPICAL HAEMOLYTIC URAEMIC SYNDROME (AHUS) IN ADULTS
Nephrology Dialysis Transplantation · 2020
- Erratum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment” Kidney Int. 2020;97:1287–1296
Kidney International · 2020
- Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab
Blood · 2019
- Blood×5
- Kidney International×3
- Kidney International Reports×2
- Clinical Nephrology×1
- Kidney Medicine×1
- Spero R. Cataland
Immunology and Microbiology · The Ohio State University
- Shangbin Yang
Immunology and Microbiology · The Ohio State University
- Alexander Röth
Immunology and Microbiology · Purdue University West Lafayette
- Margaret M. Fitzpatrick
Immunology and Microbiology · The Ohio State University
- Myda Khalid
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile